Sweden’s National Board of Health and Welfare (NT-rådet) has reversed its previous decision regarding access to the ALS drug Tofersen. Initially denied broader use, the medication will now be available to a limited group of patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). Eligibility is restricted to individuals experiencing the most rapid disease progression. This marks a significant shift, offering a potential treatment option for those with quickly deteriorating conditions. The decision follows ongoing debate surrounding the drug’s cost-effectiveness and clinical benefits. NT-rådet’s change in stance provides hope for patients facing aggressive forms of ALS. Further details regarding specific criteria for accessing Tofersen are expected to be released shortly.